VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF HLX316 FOR INJECTION (B7-H3-TARGETING SIALIDASE FC FUSION PROTEIN) FOR THE TREATMENT OF PATIENTS WITH ADVANCED/METASTATIC SOLID TUMOURS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)